Skip to main content
. 2022 Jan 19;11:740091. doi: 10.3389/fonc.2021.740091

Figure 3.

Figure 3

Cost-effectiveness acceptability curves of five immunotherapy plus chemotherapy regimens (A) Nivolumab at 100% cost, (B) Nivolumab at 60% cost, (C) Nivolumab at 40% cost, (D) Nivolumab at 20% cost. Durc, durvalumab plus chemotherapy; Atec, atezolizumab plus chemotherapy; Pemc, pembrolizumab plus chemotherapy; Nivc, nivolumab plus chemotherapy; Ipic, ipilimumab plus chemotherapy; QALY, quality-adjusted life year; WTP, willingness-to-pay.